Clinical Trials Browser

Not yet recruiting × Stomach Neoplasms × pembrolizumab × Clear all

NCT06093425 2025-12-17

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Phase 3 Not yet recruiting

Gastrointestinal

Stomach Neoplasms